Mesonephric-like adenocarcinoma of the endometrium: detailed molecular characterization of the first case showing a morphological continuum from mesonephric-like metaplasia and atypical mesonephric-like hyperplasia to adenocarcinoma.
{"title":"Mesonephric-like adenocarcinoma of the endometrium: detailed molecular characterization of the first case showing a morphological continuum from mesonephric-like metaplasia and atypical mesonephric-like hyperplasia to adenocarcinoma.","authors":"Angela Santoro, Giuseppe Angelico, Nadine Narducci, Antonio Travaglino, Alessia Piermattei, Frediano Inzani, Damiano Arciuolo, Francesca Addante, Belen Padial Urtueta, Giordana Tinnirello, Giulia Scaglione, Nicoletta D'Alessandris, Michele Valente, Angelo Minucci, Gian Franco Zannoni","doi":"10.1007/s00428-024-03972-9","DOIUrl":null,"url":null,"abstract":"<p><p>Mesonephric-like adenocarcinoma is a rare subtype of endometrial cancer, characterized by its histological and molecular overlap with mesonephric carcinoma of the uterine cervix. This study presents a unique case of mesonephric-like adenocarcinoma in the endometrium, accompanied by adjacent mesonephric-like hyperplasia and atypical mesonephric-like hyperplasia. Histologically, the transition from mesonephric metaplasia to adenocarcinoma was evident, and molecular analysis revealed shared mutations, including KRAS (p.G12D) in both atypical hyperplasia and adenocarcinoma, and a novel BCOR mutation (p.A1314Nfs*49) in the adenocarcinoma. These findings suggest a Müllerian origin of mesonephric-like adenocarcinoma via mesonephric transdifferentiation, challenging the traditional understanding of mesonephric histogenesis. The identification of these mutations underscores the potential for targeted therapies, particularly in cases with BCOR and KRAS mutations. This study is the first to document preneoplastic lesions in mesonephric-like adenocarcinoma, offering new insights into its pathogenesis and therapeutic implications.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virchows Archiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00428-024-03972-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Mesonephric-like adenocarcinoma is a rare subtype of endometrial cancer, characterized by its histological and molecular overlap with mesonephric carcinoma of the uterine cervix. This study presents a unique case of mesonephric-like adenocarcinoma in the endometrium, accompanied by adjacent mesonephric-like hyperplasia and atypical mesonephric-like hyperplasia. Histologically, the transition from mesonephric metaplasia to adenocarcinoma was evident, and molecular analysis revealed shared mutations, including KRAS (p.G12D) in both atypical hyperplasia and adenocarcinoma, and a novel BCOR mutation (p.A1314Nfs*49) in the adenocarcinoma. These findings suggest a Müllerian origin of mesonephric-like adenocarcinoma via mesonephric transdifferentiation, challenging the traditional understanding of mesonephric histogenesis. The identification of these mutations underscores the potential for targeted therapies, particularly in cases with BCOR and KRAS mutations. This study is the first to document preneoplastic lesions in mesonephric-like adenocarcinoma, offering new insights into its pathogenesis and therapeutic implications.
期刊介绍:
Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.